Kevin Gorman, CEO of Neurocrine Biosciences Inc (NBIX, Financial), sold 167,858 shares of the company on January 9, 2024, according to a recent SEC Filing. Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases and disorders.
Over the past year, the insider has sold a total of 208,937 shares and has not made any purchases of the company's stock.
The insider transaction history for Neurocrine Biosciences Inc shows a pattern of insider selling, with 0 insider buys and 54 insider sells over the past year.
On the date of the insider's recent sale, shares of Neurocrine Biosciences Inc were trading at $133.02, resulting in a market cap of $12.826 billion.
The company's price-earnings ratio stands at 70.20, which is above the industry median of 23.735 but below the company's historical median price-earnings ratio.
With the current share price of $133.02 and a GuruFocus Value of $149.64, Neurocrine Biosciences Inc has a price-to-GF-Value ratio of 0.89, indicating that the stock is considered Modestly Undervalued according to its GF Value.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
